Navigation Links
Angiotech appoints Hank McKinnell to its Board of Directors
Date:5/13/2008

VANCOUVER, May 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Dr. Hank McKinnell to its Board of Directors.

Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and the Lead Director of the Board of Directors of Moody's Corporation.

"We are honoured that Dr. McKinnell has agreed to join our Board of Directors," said Dr. William Hunter, President and CEO of Angiotech. "With his history and experience in many roles at Pfizer, including as Chairman and CEO, Dr. McKinnell brings the deep industry knowledge and extraordinary leadership qualities that we will need to facilitate our continued evolution into a significant, multinational, operating business in the life sciences sector."

Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years, held positions of increasing responsibility around the world, including service as President of Pfizer Asia. In 1984, Dr. McKinnell relocated to New York, where he served as Vice President-Strategic Planning, Chief Financial Officer, President-Pfizer Medical Device Group, President-Pfizer Pharmaceuticals Group, and President and Chief Operating Officer. He was named Chairman and Chief Executive officer in 2001 and served in this role until his retirement in the second half of 2006.

Dr. McKinnell is the Chairman Emeritus of the Business Roundtable, an association of the CEOs of America's largest companies, the Pharmaceutical Research Manufacturers Association, the Food and Drug Law Institute, and the Medical Device Manufacturers Association. He has also served as vice chairman of the World Economic Forum, as a member of the WEF Foundation Board of Trustees, and on the President's Advisory Council on HIV/AIDS.

Dr. McKinnell holds a Bachelor's Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech to participate in Bank of America Health Care Conference
2. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
3. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
4. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
5. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
6. Angiotech announces director resignation
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
9. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
10. Angiotech to participate in Lehman Brothers Healthcare Conference
11. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... its new stem cell treatment clinic in Quito, Ecuador. The new facility will ... trauma applications to patients from around the world. , The new GSCG ...
(Date:2/10/2016)... WASHINGTON , February 10, 2016 Early-career ... , Peru , Uganda ... their life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are ... sciences and epidemiology. They are also celebrated for mentoring young women scientists ...
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... York (PRWEB) , ... February ... ... (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, ... for infectious diseases and cancer. , The Human Vaccines Project brings ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:2/1/2016)... Fla. , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ... and television personality, Joey Fatone . Las Vegas ... greet fans. --> Las Vegas , where ... --> The new video ad was filmed at the Consumer ... appeared at the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):